Rifaximin in the spotlight: Are we ready to target the microbiome? by Florent Artru, Virginia Hernández-Gea

Get full text

EASL postgraduate course report: Vascular biology in chronic liver disease and clinical management implicationsKey points by Pierre-Emmanuel Rautou, Ton Lisman, Virginia Hernandez-Gea, Cristina Ripoll

Get full text

Comparable hemostatic capacity of blood taken from the portal vein compared with systemic blood in patients with cirrhosis by Annabel Blasi, Andrea Calvo, Ricard Mellado, Miguel Angel Torrente, Fanny Turon, Juan Carlos Garcia-Pagan, Virginia Hernandez-Gea, Dolors Tassies, Joan Carles Reverter, Ton Lisman

Get full text

Hemodynamic profile of terlipressin and octreotide in patients with cirrhosis and portal hypertension: a randomized, single-blind clinical trial by Valeria Perez-Campuzano, Pol Olivas, José Ferrusquía-Acosta, Sonia Torres, Roger Borras, Anna Baiges, Lara Orts, Pamela Vizcarra, Maria-Angeles Falga, Joana Codina, Sarah Shalaby, Asunción Ojeda, Fanny Turon, Virginia Hernández-Gea, Andrés Cárdenas, Juan-Carlos García-Pagán

Get full text

Impact of SARS-CoV-2 vaccination in patients with vascular liver diseases: Observations from a VALDIG multicenter study by Valeria Perez-Campuzano, Pierre-Emmanuel Rautou, Thomas Marjot, Michael Praktiknjo, Edilmar Alvarado-Tapias, Laura Turco, Luis Ibáñez-Samaniego, Carlos González-Alayón, Ángela Puente, Elba Llop, Macarena Simón-Talero, Carmen Álvarez-Navascués, Thomas Reiberger, Xavier Verhelst, Luis Tellez, Johanna Birte Bergmann, Lara Orts, Giuseppe Grassi, Anna Baiges, Payance Audrey, Jonel Trebicka, Candid Villanueva, Maria Cristina Morelli, Sam Murray, Georgina Meacham, Marc Luetgehetmann, Julian Schulze zur Wiesch, Juan-Carlos García-Pagán, Eleanor Barnes, Aurélie Plessier, Virginia Hernández-Gea

Get full text